Bulletin of Experimental Biology and Medicine

, Volume 165, Issue 3, pp 344–346 | Cite as

Evaluation of the Possibility of Correction of Doxorubicin-Induced Chronic Heart Failure in the Experiment with 3-Hydroxypyridine Acetylcysteinate and 3-Hydroxypyridine Succinate

  • M. N. Zamotaeva
  • V. I. Inchina
  • V. V. KonorevEmail author
  • Yu. V. Kuznetsov
  • N. D. Kuz’michev

The possibility of correction of morphological changes in the myocardium and biochemical parameters of the blood with 3-hydroxypyridine acetylcysteinate in a dose of 25 mg/kg was studied in the model of doxorubicin-induced chronic heart failure in rats. It was found that 3-hydroxypyridine acetylcysteinate in a dose of 25 mg/kg produced less pronounced cardio-protective effect in experimental chronic heart failure than 3-hydroxypyridine succinate.

Key Words

regenerative and plastic heart failure 3-hydroxypyridine acetylcysteinate 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Andreeva NN. The experimental and clinical aspects of the application of Meksidol in hypoxia. Med. Al’manakh. 2009;(4):193-197. Russian.Google Scholar
  2. 2.
    Arzamastseva NE, Lankin VZ, Konovalova GG, Tikhaze AK, Ageev FT, Lapina YV, Narusov OY, Mareev VY, Belenkov YN. Oxidative stress in patients with chronic heart failure and type 2 diabetes mellitus. Bull. Exp. Biol. Med. 2007;143(2):207-209.CrossRefPubMedGoogle Scholar
  3. 3.
    Vereshchagina GN, Irkhina IS, Ermakova ÉN, Poltaranina GG, Novikova ON. Mexidol in scheme of combined therapy of chronic heart failure of the 2nd-3nd functional classes. Kardiol. Serd.-Sosud. Khirurgiya. 2013;6(6):60-63. Russian.Google Scholar
  4. 4.
    Vladimirov YuA, Archkov AI. Lipid Peroxidation in Biological Membranes. Moscow, 1972. Russian.Google Scholar
  5. 5.
    Zamotaeva MN, Inchina VI, Chairkin IN. Efficiency of structurally different antioxidants in combined myocardial damage in mice. Bull Exp Biol Med. 2012;152(3):318-320.CrossRefPubMedGoogle Scholar
  6. 6.
    Zamotaeva MN, Inchina VI, Chairkin IN, Drozdov IA, Kuzmichev ND, Kuznetsov YuV. A comparative study of cardioprotective properties of succinate 3-oxipiridine and acetylcisteinate 3-oxipiridine at experimental chronical heart deficiency. Sovremen. Probl. Nauki Obrazovaniya. 2013;(4):140. Russian.Google Scholar
  7. 7.
    Zamotaeva MN, Inchina VI, Chairkin IN, Drozdov IA, Kuzmichev ND, Kuznetsov YV. A comparative analysis of 3-oxypiridine succinate and 3-oxypiridine acetylcisteinate cardioprotactive properties at experimental acute myocardium infarction. Fundamental. Issled. 2013;(12-3):479-482. Russian.Google Scholar
  8. 8.
    Inchina VI, Vintin NA, Zor’kina AV, Sernov LN, Kostin YaV. Pharmacological rehabilitation under conditions of long-term restrain stress. Mezhdunarod. Zh. Immunoreab. 1996;(2):90. Russian.Google Scholar
  9. 9.
    Korolyuk MA, Ivanova LI, Maiorova IG, Tokarev VE. A method for measuring catalase activity. Lab. Delo. 1988;(1):16-19. Russian.Google Scholar
  10. 10.
    Litvitskii PF. Pathogenetic and adaptive changes in the heart during its regional ischemia followed by coronary blood flow resumption. Patol. Fiziol. 2002;(2):2-12. Russian.Google Scholar
  11. 11.
    Luk’yanova LD. Mitochondrial dysfunction is a typical pathological process and molecular mechanism of hypoxia. Problems of Hypoxia: Molecular, Physiological, and Medical Aspects. Luk’yanova LD, Ushakov IB, eds. Moscow; Voronezh, 2004. P. 8-50. Russian.Google Scholar
  12. 12.
    Maksimovich NE, Zinchuk VV, Maslakov DA. The intensity of oxidative stress in rat brain during ischemia/reperfusion under conditions of correction of L-arginine-NO-system. Ross. Fiziol. Zh. 2005;91(4):385-393. Russian.Google Scholar
  13. 13.
    Syrkin AL, Dobrovol’skii AV. Metabolism corrector anti-ischemic drugs. Consilium Medicum. 2002;4(11):572-575. Russian.Google Scholar
  14. 14.
    De Windt LJ, Willems J, Roemen TH, Coumans WA, Reneman RS, Van Der Vusse GJ, Van Bilsen M. Ischemic: reperfused isolated working mouse heart: membrane damage and type II A phospholipase A. Am. J. Physiol. Heart Cirс. Physiol. 2001;280(6):H2572-H2580.Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • M. N. Zamotaeva
    • 1
  • V. I. Inchina
    • 1
  • V. V. Konorev
    • 1
    Email author
  • Yu. V. Kuznetsov
    • 2
  • N. D. Kuz’michev
    • 1
  1. 1.N. P. Ogarev Mordovian National Research State UniversitySaranskRussia
  2. 2.N. M. Emanuel Institute of Biochemical PhysicsMoscowRussia

Personalised recommendations